{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:31:24Z","timestamp":1790796684707,"version":"4.1.0"},"reference-count":63,"publisher":"BMJ","issue":"10","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2022,5,24]]},"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Several papers have shown that programmed death-ligand 1 (PD-L1) expression is a relevant predictive biomarker in anti-PD-L1 cancer immunotherapy. While its role in several human cancers is correlated with poor prognosis and resistance to anticancer therapies, in thyroid cancers the role of PD-L1 remains questionable. Few articles have studied PD-L1 in thyroid fine-needle aspiration cytology (FNAC), demonstrating a possible correlation with papillary thyroid carcinoma. However, its role in oncocytic thyroid lesions remains controversial. We accordingly examine the performance of PD-L1 immunostaining in liquid based cytology (LBC) from oncocytic lesions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>From January 2019 to March 2021, 114 thyroid lesions diagnosed by FNAC from lesions with a predominant oncocytic component, were enrolled for evaluation by PD-L1 immunostaining on both LBC and corresponding histology samples.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The FNAC cohort included 51 benign (B, negative controls), 4 atypia of undetermined significance\/follicular lesions of undetermined significance (AUS\/FLUS), 57 follicular lesions (follicular neoplasm\/suspicious for FN, FN\/SFN) and 2 suspicious for malignancy (SFM) cases. Fifty-four cases (11B, 2 AUS\/FLUS, 39 FN\/SFN and 2 SFM) had histological follow-up including: 1B case resulted as a hyperplastic oxyphilic nodule in Hashimoto thyroiditis (HT), 10B as goitre, 2 AUS\/FLUS cases as oncocytic adenomas (OAs); 39 FN\/SFN included 27 OAs, 4 FA and 8 oncocytic follicular carcinoma (OFC). The two SFM cases were diagnosed on histopathology as OAs. Increased plasma membrane and cytoplasmic PD-L1 expression were found in 47 cases of the LBC cases (41.2%). Among the histological series, 67.3% of OAs and 75% of OFC had PD-L1 expression, while negative PD-L1 was found in hyperplastic oncocytic cells in HT. A positivity in more than 30% of the neoplastic cells was found in 72.9% of the cases including six OFC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These data suggest that PD-L1 expression is expressed in oncocytic thyroid lesions. While weak PD-L1 expression failed to discriminate benign from malignant lesions, OFC demonstrated more intense cytoplasmic and membranous expression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jclinpath-2022-208215","type":"journal-article","created":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T13:54:08Z","timestamp":1655214848000},"page":"671-677","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Update regarding the role of PD-L1 in oncocytic thyroid lesions on cytological samples"],"prefix":"10.1136","volume":"76","author":[{"given":"Marco","family":"Dell'Aquila","sequence":"first","affiliation":[{"name":"Anatomic Pathology and Histology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Tralongo","sequence":"additional","affiliation":[{"name":"Anatomic Pathology and Histology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Granitto","sequence":"additional","affiliation":[{"name":"Anatomic Pathology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Martini","sequence":"additional","affiliation":[{"name":"Anatomic Pathology and Histology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Capodimonti","sequence":"additional","affiliation":[{"name":"Anatomic Pathology and Histology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Curatolo","sequence":"additional","affiliation":[{"name":"Anatomic Pathology and Histology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Fiorentino","sequence":"additional","affiliation":[{"name":"Anatomic Pathology and Histology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Pontecorvi","sequence":"additional","affiliation":[{"name":"Endocrinology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Fadda","sequence":"additional","affiliation":[{"name":"Anatomic Pathology and Histology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celestino Pio","family":"Lombardi","sequence":"additional","affiliation":[{"name":"Endocrine Surgery, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maco","family":"Raffaelli","sequence":"additional","affiliation":[{"name":"Endocrine Surgery, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liron","family":"Pantanowitz","sequence":"additional","affiliation":[{"name":"Department of Pathology & Clinical Labs, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi Maria","family":"Larocca","sequence":"additional","affiliation":[{"name":"Anatomic Pathology and Histology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3819-4229","authenticated-orcid":false,"given":"Esther Diana","family":"Rossi","sequence":"additional","affiliation":[{"name":"Anatomic Pathology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,6,14]]},"reference":[{"key":"2025120519551302000_76.10.671.1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.192461099"},{"key":"2025120519551302000_76.10.671.2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-0983"},{"key":"2025120519551302000_76.10.671.3","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of Anti\u2013PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025120519551302000_76.10.671.4","unstructured":"Tsao MS , Kerr KM , Dacic S , et al . Atlas of PD-L1 immunoistochemistry testing in lung cancer. 1st edn. Aurora, CO: International association for the study of lung cancer, 2017."},{"key":"2025120519551302000_76.10.671.5","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2072-1439.2015.02.13"},{"key":"2025120519551302000_76.10.671.6","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/cncy.21987","article-title":"Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations","volume":"126","author":"Noll","year":"2018","journal-title":"Cancer Cytopathol"},{"key":"2025120519551302000_76.10.671.7","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1001\/jamaoncol.2016.3015","article-title":"A quantitative comparison of antibodies to programmed cell death 1 ligand 1","volume":"3","author":"Gaule","year":"2017","journal-title":"JAMA Oncology"},{"key":"2025120519551302000_76.10.671.8","first-page":"205","article-title":"Efficiency of cytology samples for PD-L1 evaluation and comparison with tissue samples","volume":"36","author":"Kulac","year":"2020","journal-title":"Turk Patoloji Derg"},{"key":"2025120519551302000_76.10.671.9","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/cncy.22224","article-title":"PD\u2010L1 and thyroid cytology: a possible diagnostic and prognostic marker","volume":"128","author":"Dell\u2019Aquila","year":"2020","journal-title":"Cancer Cytopathol"},{"key":"2025120519551302000_76.10.671.10","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-0255"},{"key":"2025120519551302000_76.10.671.11","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0000000000000531"},{"key":"2025120519551302000_76.10.671.12","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jamaoncol.2017.0013","article-title":"A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer","volume":"3","author":"Rimm","year":"2017","journal-title":"JAMA Oncology"},{"key":"2025120519551302000_76.10.671.13","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13000-017-0662-z","article-title":"PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma","volume":"12","author":"Bai","year":"2017","journal-title":"Diagn Pathol"},{"key":"2025120519551302000_76.10.671.14","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2013.130"},{"key":"2025120519551302000_76.10.671.15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1001\/jamaoncol.2015.4685","article-title":"Pd-L1 testing in cancer: challenges in companion diagnostic development","volume":"2","author":"Hansen","year":"2016","journal-title":"JAMA Oncol"},{"key":"2025120519551302000_76.10.671.16","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1365-2303.2004.00129.x","article-title":"ERCP-directed brush cytology prepared by the ThinPrep method: test performance and morphology of 149 cases","volume":"15","author":"Duggan","year":"2004","journal-title":"Cytopathology"},{"key":"2025120519551302000_76.10.671.17","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/cyt.12634","article-title":"The use of cytological material in melanoma for programmed death ligand 1 immunostaining","volume":"30","author":"Bashover","year":"2019","journal-title":"Cytopathology"},{"key":"2025120519551302000_76.10.671.18","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.jasc.2018.07.005","article-title":"The usefulness of various cytologic specimen preparations for PD-L1 immunostaining in non-small cell lung carcinoma","volume":"7","author":"Arriola","year":"2018","journal-title":"J AM Soc Cytopathol"},{"key":"2025120519551302000_76.10.671.19","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/cncy.21973","article-title":"Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas","volume":"126","author":"Russell-Goldman","year":"2018","journal-title":"Cancer Cytopathol"},{"key":"2025120519551302000_76.10.671.20","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/cncy.21937","article-title":"PD-L1 expression in non-small cell lung carcinoma: comparison among cytology, small biopsy, and surgical resection specimens","volume":"125","author":"Heymann","year":"2017","journal-title":"Cancer Cytopathol"},{"key":"2025120519551302000_76.10.671.21","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0000000000000540"},{"key":"2025120519551302000_76.10.671.22","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s12022-018-9540-9","article-title":"Papillary thyroid carcinoma emerging from Hashimoto thyroiditis demonstrates increased PD-L1 expression, which persists with metastasis","volume":"29","author":"Lubin","year":"2018","journal-title":"Endocr Pathol"},{"key":"2025120519551302000_76.10.671.23","first-page":"42951","article-title":"Ctla-4 and PD-1 ligand gene expression in epithelial thyroid cancers","volume":"17","author":"Tuccilli","year":"2018","journal-title":"Int. J Endocrinol"},{"key":"2025120519551302000_76.10.671.24","doi-asserted-by":"publisher","DOI":"10.4132\/jptm.2017.07.26"},{"key":"2025120519551302000_76.10.671.25","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ebiom.2017.03.031","article-title":"Programmed Death - Ligand 1 Expression Distinguishes Invasive Encapsulated Follicular Variant of Papillary Thyroid Carcinoma from Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features","volume":"18","author":"Fu","year":"2017","journal-title":"EBioMedicine"},{"key":"2025120519551302000_76.10.671.26","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/his.13230","article-title":"CD70 and PD-L1 in anaplastic thyroid cancer - promising targets for immunotherapy","volume":"71","author":"Zwaenepoel","year":"2017","journal-title":"Histopathology"},{"key":"2025120519551302000_76.10.671.27","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-3756"},{"key":"2025120519551302000_76.10.671.28","doi-asserted-by":"crossref","first-page":"32318","DOI":"10.18632\/oncotarget.8698","article-title":"Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants","volume":"7","author":"Chowdhury","year":"2016","journal-title":"Oncotarget"},{"key":"2025120519551302000_76.10.671.29","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-16-0421"},{"key":"2025120519551302000_76.10.671.30","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5380-3"},{"key":"2025120519551302000_76.10.671.31","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0272-2712(18)30434-7","article-title":"Fine needle aspiration cytology of the thyroid: a 12-year experience with 11,000 biopsies","volume":"13","author":"Gharib","year":"1993","journal-title":"Clin Lab Med"},{"key":"2025120519551302000_76.10.671.32","unstructured":"Perros P , Boelaert K , Colley S . Guidelines for the management of thyroid cancer. In: Report of the thyroid cancer guidelines update group. 3rd edition. London: British Thyroid Association, Royal College of Physicians, 2007."},{"key":"2025120519551302000_76.10.671.33","first-page":"405","article-title":"Cytological classification of thyroid nodules. proposal of the SIAPEC-IAP Italian consensus Working group","volume":"102","author":"Fadda","year":"2010","journal-title":"Pathologica"},{"key":"2025120519551302000_76.10.671.34","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-014-0062-0"},{"key":"2025120519551302000_76.10.671.35","doi-asserted-by":"crossref","unstructured":"Ali S , Cibas ES . The Bethesda system for reporting thyroid cytopathology. 2nd edn. Berlin: Springer, 2018.","DOI":"10.1007\/978-3-319-60570-8"},{"key":"2025120519551302000_76.10.671.36","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-11-0181"},{"key":"2025120519551302000_76.10.671.37","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/cyt.12555","article-title":"Morphology combined with ancillary techniques: an algorithm approach for thyroid nodules","volume":"29","author":"Rossi","year":"2018","journal-title":"Cytopathology"},{"key":"2025120519551302000_76.10.671.38","doi-asserted-by":"publisher","DOI":"10.1002\/cncy.21416"},{"key":"2025120519551302000_76.10.671.39","doi-asserted-by":"publisher","DOI":"10.1002\/cncy.21258"},{"key":"2025120519551302000_76.10.671.40","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1159\/000329029","article-title":"Liquid-Based cytology in fine-needle aspiration biopsies of the thyroid gland","volume":"55","author":"Fadda","year":"2011","journal-title":"Acta Cytol"},{"key":"2025120519551302000_76.10.671.41","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00428-018-2357-6","article-title":"In papillary thyroid carcinoma, expression by immunohistochemistry of BRAF V600E, PD-L1, and PD-1 is closely related","volume":"472","author":"Bai","year":"2018","journal-title":"Virchows Arch"},{"key":"2025120519551302000_76.10.671.42","unstructured":"American Joint Commission on Cancer (AJCC) . Cancer staging atlas. 8th edn, 2017."},{"key":"2025120519551302000_76.10.671.43","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1001\/jamaoncol.2016.0386","article-title":"Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors","volume":"2","author":"Nikiforov","year":"2016","journal-title":"JAMA Oncol"},{"key":"2025120519551302000_76.10.671.44","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/cncy.21941","article-title":"Programmed death-ligand 1 testing of lung cancer cytology specimens obtained with bronchoscopy","volume":"126","author":"Stoy","year":"2018","journal-title":"Cancer Cytopathol"},{"key":"2025120519551302000_76.10.671.45","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2014.0134"},{"key":"2025120519551302000_76.10.671.46","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1089\/thy.2016.0228","article-title":"Programmed Death-Ligand 1 expression in papillary thyroid cancer and its correlation with clinicopathologic factors and recurrence","volume":"27","author":"Shi","year":"2017","journal-title":"Thyroid"},{"key":"2025120519551302000_76.10.671.47","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1210\/jc.2015-4227","article-title":"Tumor-Infiltrating T cells and the PD-1 checkpoint pathway in advanced differentiated and anaplastic thyroid cancer","volume":"101","author":"Bastman","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2025120519551302000_76.10.671.48","doi-asserted-by":"crossref","first-page":"73068","DOI":"10.18632\/oncotarget.12230","article-title":"The efficacy and safety of anti-PD-1\/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"2025120519551302000_76.10.671.49","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e318246b527"},{"key":"2025120519551302000_76.10.671.50","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-0727"},{"key":"2025120519551302000_76.10.671.51","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3431"},{"key":"2025120519551302000_76.10.671.52","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-12-0313"},{"key":"2025120519551302000_76.10.671.53","doi-asserted-by":"publisher","DOI":"10.3410\/f.717987086.793472329"},{"key":"2025120519551302000_76.10.671.54","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19850215)55:4<805::AID-CNCR2820550419>3.0.CO;2-Z"},{"key":"2025120519551302000_76.10.671.55","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-002-6612-1"},{"key":"2025120519551302000_76.10.671.56","unstructured":"Lloyd RV , Osamura RY , Kl\u00f6ppel G , et al , eds. WHO Classification of Tumours of Endocrine Organs. 4th edn. Lyon, France: IARC, 2017."},{"key":"2025120519551302000_76.10.671.57","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.pathol.2019.11.007","article-title":"Pd-L1 expression in papillary thyroid cancer with and without lymphocytic thyroiditis: a cross sectional study","volume":"52","author":"Fadia","year":"2020","journal-title":"Pathology"},{"key":"2025120519551302000_76.10.671.58","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-014-9876-5"},{"key":"2025120519551302000_76.10.671.59","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s12022-018-9514-y","article-title":"PD-L1 and IDO1 are expressed in poorly differentiated thyroid carcinoma","volume":"29","author":"Rosenbaum","year":"2018","journal-title":"Endocr Pathol"},{"key":"2025120519551302000_76.10.671.60","doi-asserted-by":"crossref","first-page":"17194","DOI":"10.18632\/oncotarget.7839","article-title":"Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer","volume":"7","author":"Brauner","year":"2016","journal-title":"Oncotarget"},{"key":"2025120519551302000_76.10.671.61","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.2217\/fon.13.89","article-title":"And B7H1 shield","volume":"9","author":"Cunha","year":"2013","journal-title":"Future Oncol"},{"key":"2025120519551302000_76.10.671.62","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.3390\/ijms20061405","article-title":"Pd-1 ligand expression in epithelial thyroid cancers: potential clinical implications","volume":"20","author":"Ulisse","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2025120519551302000_76.10.671.63","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.surg.2017.04.033","article-title":"Predictive relevance of programmed cell death protein 1 and tumor-infiltrating lymphocyte expression in papillary thyroid cancer","volume":"163","author":"Aghajani","year":"2018","journal-title":"Surgery"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jclinpath-2022-208215","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T03:55:32Z","timestamp":1764993332000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jclinpath-2022-208215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,14]]},"references-count":63,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,9,19]]},"published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1136\/jclinpath-2022-208215"],"URL":"https:\/\/doi.org\/10.1136\/jclinpath-2022-208215","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,14]]}}}